Zurich, 2. February 2009. Axentis Pharma AG is to present its contempo successes in developing and costs a new ameliorative conception for alleviative abiding lung ache at the 2nd Annual European Life Science CEO Forum in Zurich, Switzerland. This arrive allocution comes just three weeks afterwards the aggregation was asked to present its contempo achievements at the Biotech Showcase 2009 in San Francisco, USA. Part of the company's advancing success adventure is a contempo basic access that was awfully able-bodied subscribed by absolute clandestine investors.
SIX Swiss Exchange AG is Europe's arch banal barter for activity science companies. Its advocacy of the European Life Science CEO Forum for Partnering & Investing helps accomplish this one of Europe's a lot of absolute and awful transactional partnering events.
At this year's appointment (February 3 - 4) Dr. Susanne Acklin, COO of Axentis Pharma AG, will be presenting the company's contempo successes in developing and costs a new ameliorative conception for alleviative abiding lung disease. "2008 was acutely acknowledged for Axentis", explains Acklin. "Our advance artefact ARB-CF0223 - a liposomal conception of tobramycin, delivered anon to the website of infection via accepted nebulisers - produced actual acceptable abstracts from a appearance I analytic trial; we accomplished a analytic appearance II balloon and a consecutive basic access was able-bodied accustomed - and subscribed - by our absolute clandestine investors. We are actual blessed with the accepted position of Axentis and accede it the appropriate time to present the aggregation to accomplished institutional investors. That's why we are accommodating actuality in Zurich."
Dr. Acklin aswell serves as Vice President Life Sciences at Venture Valuation AG, a arch absolute Swiss aggregation specializing in assessing, account and ecology start-up companies. In this position Acklin has admired able-bodied over 100 activity science companies and afresh absitively to accompany Axentis.
The accretion absorption in Axentis and its advance artefact aswell resulted in a presentation at the Biotech Showcase 2009 in San Francisco by the company's CEO Dr. Helmut Brunar. Amongst the able-bodied over 225 companies present at the event, he had the advantage of presenting the company's success. "Our banking position is abundantly able that we absitively to delay with a above annular of costs until aboriginal 2010. Now is accordingly the appropriate time to present ourselves in the best ablaze to able investors. Our advance artefact ARB-CF0223 - aswell accepted as Fluidosome(R) tobramycin - is accepted to accomplish a aiguille anniversary about-face of approx. 100 actor EUR aural 5 years of bazaar launch. The investment that we will be gluttonous in aboriginal 2010 will see us through until this access assimilate the market. I accede Axentis an acutely adorable investment option. The acknowledgment I accustomed in San Francisco absolutely accepted this claimed judgment."
The next befalling to accommodated assembly of Axentis Pharma at European conferences will be at the BioSquare in Lyon, France, on March 9 to 11.
About Axentis Pharma AG (www.axentispharma.com)
Axentis Pharma AG is a Swiss aggregation amid in Zurich with a focus on developing ameliorative solutions for respiratory diseases, a lot of noticeably cystic fibrosis. Axentis' advance artefact is in appearance II analytic trials. Market allotment / approval is accepted in 2012.
About Fluidosome(R) technology
Axentis Pharma's Fluidosome(R) technology uses biocompatible lipids autogenous to the lung that are formulated into baby liposomes. This nanocapsule belvedere offers absolute abeyant to baby to unmet medical needs such as cystic fibrosis and added respiratory diseases. In the case of Fluidosome(R) tobramycin, the alternation amid tobramycin and the microbial corpuscle is triggered if the liposomes attach to the alien corpuscle membrane. Tobramycin again penetrates into the close corpuscle alcove of the microbial cell, which leads to accelerated corpuscle death.
About cystic fibrosis
Cystic fibrosis is the a lot of accepted life-threatening ancestral ache amidst Caucasian populations. The ache is acquired by a alteration in the CFTR (cystic fibrosis transmembrane conductance regulator) gene begin on chromosome 7. This alteration causes added beard deposits on close membranes. Lung complications represent the a lot of austere appearance of the ache - and the acumen for the top bloodshed amount amidst patients. Such complications generally absorb infection of the bronchi by the bacilli Pseudomonas aeruginosa. Chronic inflammations again could cause lung functions to become blocked. In accession to the breakdown of lung tissue, this aswell leads to bronchiectasis and lung failure.
For added information, amuse contact:
Axentis Pharma AG
Limmatquai 138
8001 Zurich
Switzerland
T +41 79 525 6668
E board@axentispharma.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 1 505 70 44
E contact@prd.at
订阅：
博文评论 (Atom)
没有评论:
发表评论